ACTRIMS 2022 | CanProCo: understanding factors related to progression in MS

Jiwon Oh, MD, PhD, St. Michael’s Hospital, University of Toronto, Toronto, Canada, shares an overview of the ongoing CanProCo study. CanProCo is a national Canadian prospective cohort study designed to aid in understanding the factors related to progression in multiple sclerosis (MS). Factors range from biological to health administrative and include genetics, geographical location, as well as distance from a health clinic. A total of 1000 patients were selected and are being followed for a minimum of five years. The CanProCo trial aims to contribute knowledge on the progression of MS to help inform the development of novel treatments targeting progression. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.